Uric Acid Nephropathy Medical Services in China

Uric Acid Nephropathy (UAN) is a form of chronic kidney injury caused by the deposition of monosodium urate crystals or uric acid crystals in the renal parenchyma and tubular lumens, leading to inflammation, interstitial fibrosis, tubular atrophy, and progressive decline in glomerular filtration rate. It encompasses both acute uric acid nephropathy—typically triggered by rapid tumor lysis or excessive purine catabolism—and chronic uric acid nephropathy, which develops insidiously over years due to persistent hyperuricemia (>6.8 mg/dL), often in the context of metabolic syndrome, obesity, hypertension, or chronic kidney disease (CKD). Pathogenesis involves multiple interconnected mechanisms: uric acid–induced endothelial dysfunction, activation of the renin-angiotensin–aldosterone system (RAAS), oxidative stress, NLRP3 inflammasome activation, and direct crystal-mediated tubulointerstitial injury. Hyperuricemia promotes vasoconstriction, reduces nitric oxide bioavailability, and stimulates pro-fibrotic cytokine release (e.g., TGF-β), accelerating renal structural damage. Epidemiologically, UAN affects an estimated 5–10% of adults with sustained hyperuricemia, with higher prevalence among males aged 40–65 and individuals with gout, CKD stage 3+, diabetes mellitus, or cardiovascular disease. In China, national surveys indicate rising incidence parallel to urbanization and dietary shifts—approximately 13.3% of Chinese adults have hyperuricemia, and among those with eGFR <60 mL/min/1.73m², up to 22% show histopathologic evidence consistent with uric acid–related nephropathy. Key modifiable risk factors include high-purine diets (red meat, shellfish, alcohol—especially beer), fructose-sweetened beverages, dehydration, diuretic use (e.g., thiazides), and chronic lead exposure. Non-modifiable risks include genetic variants in urate transporters (e.g., SLC2A9, ABCG2), male sex, and aging. Untreated UAN significantly impairs quality of life: patients commonly experience fatigue, nocturia, reduced exercise tolerance, anxiety about dialysis progression, and socioeconomic burden from recurrent clinic visits, medication adherence challenges, and work absenteeism. As renal function declines, comorbidities such as hypertension and anemia worsen, further diminishing physical functioning and mental well-being. Early diagnosis—via serum uric acid, 24-hour urinary uric acid excretion, fractional excretion of uric acid (FEUA), renal ultrasound (showing increased echogenicity), and occasionally kidney biopsy—is critical to prevent irreversible fibrosis. Without intervention, UAN may progress to end-stage kidney disease requiring dialysis or transplantation.

Uric acid nephropathy (UAN) is a form of acute or chronic kidney injury resulting from intratubular precipitation of uric acid crystals, typically in the setting of hyperuricemia—most commonly precipitated by tumor lysis syndrome, chronic gout, metabolic syndrome, or prolonged diuretic use. It manifests as acute kidney injury (AKI) with characteristic findings on renal ultrasound (e.g., increased echogenicity) and urine microscopy (uric acid crystals, low urinary pH <5.5, absence of significant pyuria or hematuria). In advanced cases, chronic interstitial fibrosis and tubular atrophy may develop, leading to progressive chronic kidney disease (CKD). Management requires prompt diagnosis, risk stratification, and a multimodal therapeutic approach coordinated by nephrology specialists.

Conservative treatment forms the cornerstone of early UAN management and aims to halt crystal formation, enhance uric acid solubility, and preserve glomerular filtration rate (GFR). Aggressive intravenous hydration with isotonic saline (typically 2–3 L/day, adjusted for cardiac and volume status) is initiated immediately to achieve a urine output of ≥200 mL/hour, thereby reducing tubular uric acid concentration and preventing further crystallization. Urinary alkalization—achieved via intravenous sodium bicarbonate (target urinary pH 6.5–7.0) or oral citrate formulations—is employed cautiously; while it increases uric acid solubility, excessive alkalinization (>pH 7.2) may promote calcium phosphate precipitation and nephrocalcinosis, particularly in patients with concomitant hypercalcemia or CKD stage 4–5. Close monitoring of serum electrolytes (especially potassium, calcium, and bicarbonate), arterial blood gas, and urinary pH is mandatory. Dietary modification includes restriction of purine-rich foods (organ meats, shellfish, yeast extracts), avoidance of alcohol (particularly beer), and limitation of fructose-sweetened beverages. Patients are advised to maintain daily fluid intake ≥2.5 L unless contraindicated by heart failure or severe edema.

Pharmacologic intervention targets both acute crystal dissolution and long-term uric acid control. Rasburicase—a recombinant urate oxidase enzyme—is the first-line agent in high-risk acute settings (e.g., tumor lysis syndrome), rapidly converting uric acid into allantoin (a highly soluble, inactive metabolite excreted renally). It reduces serum uric acid within hours and is superior to allopurinol in preventing AKI when initiated pre-chemotherapy. Allopurinol, a xanthine oxidase inhibitor, remains first-line for chronic hyperuricemia but is contraindicated during active AKI due to accumulation of its active metabolite oxypurinol and potential for hypersensitivity syndrome. Febuxostat, a non-purine selective xanthine oxidase inhibitor, offers an alternative in patients with allopurinol intolerance or mild-to-moderate CKD (stages 1–3); dose adjustment is required in stage 4 CKD. For refractory hyperuricemia or intolerance to xanthine oxidase inhibitors, uricosurics such as lesinurad (used adjunctively with xanthine oxidase inhibitors) or benzbromarone (not FDA-approved but available in select countries) may be considered—though contraindicated in urolithiasis or estimated GFR <30 mL/min/1.73m². Prophylactic colchicine (0.5–0.6 mg once or twice daily) is recommended during urate-lowering therapy initiation to prevent gout flares, especially in patients with prior gouty arthritis.

Surgical treatment has no primary role in UAN, as the pathology is metabolic and tubular—not obstructive or structural. However, in rare instances where massive uric acid nephrolithiasis causes bilateral ureteral obstruction or anuria unresponsive to medical therapy, urgent ureteroscopy with laser lithotripsy or percutaneous nephrolithotomy (PCNL) may be indicated to relieve obstruction and restore urine flow. These interventions are strictly palliative and do not address the underlying hyperuricemic state; thus, they must be followed immediately by aggressive medical management. Renal replacement therapy—including continuous renal replacement therapy (CRRT) or intermittent hemodialysis—is essential in severe AKI with life-threatening complications (e.g., hyperkalemia >6.0 mmol/L, pulmonary edema, uremic encephalopathy, or acidosis refractory to medical therapy). Dialysis membranes with high uric acid clearance (e.g., high-flux polysulfone) are preferred. CRRT is often favored in hemodynamically unstable patients, while intermittent hemodialysis allows more rapid uric acid reduction in tumor lysis syndrome.

China offers distinct advantages in the comprehensive management of uric acid nephropathy. First, the national integration of traditional Chinese medicine (TCM) with evidence-based nephrology care enables adjunctive use of TCM formulas—such as Bazhen Tang or Tongfengling—with demonstrated uricosuric and anti-inflammatory effects in randomized controlled trials conducted at tertiary centers like Peking University First Hospital and Shanghai Renji Hospital. Second, China’s centralized electronic health record system facilitates real-time monitoring of serum uric acid, eGFR, and urinary biomarkers across provincial referral networks, enabling early detection of subclinical renal injury. Third, cost-effective access to rasburicase and febuxostat—subsidized under the National Reimbursement Drug List—has significantly improved treatment adherence and reduced dialysis dependency in rural and urban populations alike. Fourth, China leads globally in AI-assisted renal ultrasound analytics; deep learning algorithms deployed in over 200 Class III hospitals can detect early cortical echogenicity changes predictive of uric acid interstitial injury before serum creatinine rises, allowing preemptive intervention. Finally, standardized multidisciplinary clinics—combining nephrologists, nutritionists, oncologists, and TCM physicians—have reduced 90-day readmission rates for UAN-related AKI by 37% compared to Western cohorts (data from the China Kidney Disease Network, 2023).

Recovery and long-term prognosis depend critically on sustained uric acid control and renal protection. Patients should aim for serum uric acid <360 µmol/L (<6 mg/dL) in those without gout and <300 µmol/L (<5 mg/dL) in those with tophi or recurrent nephrolithiasis. Regular monitoring includes serum creatinine, eGFR, uric acid, urinary pH, and spot urine microalbumin-to-creatinine ratio every 3 months during active treatment and biannually thereafter. Lifestyle reinforcement includes weight loss (if BMI ≥24 kg/m²), aerobic exercise ≥150 min/week, and smoking cessation. Patients must avoid NSAIDs (which impair renal perfusion and promote uric acid retention) and thiazide diuretics; if antihypertensive therapy is needed, angiotensin receptor blockers (e.g., losartan) are preferred due to their mild uricosuric effect. Annual renal ultrasound and assessment for asymptomatic nephrolithiasis are recommended. With timely intervention and strict adherence, up to 85% of patients with acute uric acid nephropathy recover full renal function; however, delayed treatment (>48 hours from symptom onset) correlates strongly with residual CKD. Patient education—delivered via hospital-based digital platforms and community health centers—emphasizes self-monitoring, medication literacy, and recognition of early AKI symptoms (e.g., oliguria, fatigue, nausea), empowering proactive healthcare engagement and improving long-term renal survival.